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Abstract Acute lung injury (ALI) and its more severe
form, acute respiratory distress syndrome (ARDS), is char-
acterized by acute inflammation, disruption of the alveolar-
capillary barrier, and in the organizing stage by alveolar
pneumocytes hyperplasia and extensive lung fibrosis. The
cellular and molecular mechanisms leading to the develop-
ment of ALI/ARDS are not completely understood, but there
is evidence that reactive oxygen species (ROS) generated by
inflammatory cells as well as epithelial and endothelial cells
are responsible for inflammatory response, lung damage, and
abnormal repair. Among all ROS-producing enzymes, the
members of NADPH oxidases (NOXs), which are widely
expressed in different lung cell types, have been shown to
participate in cellular processes involved in the maintenance
of lung integrity. It is not surprising that change in NOXs’
expression and function is involved in the development of
ALI/ARDS. In this context, the use of NOX inhibitors could
be a possible therapeutic perspective in the management of
this syndrome. In this article, we summarize the current
knowledge concerning some cellular aspects of NOXs
localization and function in the lungs, consider their contri-
bution in the development of ALI/ARDS and discuss the
place of NOX inhibitors as potential therapeutical target.
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Abbreviations
ALI Acute lung injury
ARDS Acute respiratory distress syndrome
BAL Bronchoalveolar lavage
ROS Reactive oxygen species
HM Hyaline membranes
LPS Lipopolysaccharide
TNF-a Tumor necrosis factor-a
ICAM-1 Intracellular adhesion molecule-1
EC Endothelial cells
TGF-b1 Transforming growth factor-b1
IPF Idiopathic pulmonary fibrosis
IRF-3 Interferon regulatory factor-3
AP1 Activator protein 1
NF-jB Nucleor factor jB




Acute lung injury (ALI) and acute respiratory distress
syndrome (ARDS), which is the most severe form, is
associated with a high mortality (50–80 %). ALI/ARDS
affects a large number of patients entering intensive care
units and is defined by bilateral pulmonary infiltrates on
chest radiograph, hypoxemic respiratory failure measured
by a partial pressure of arterial oxygen (PaO2)/fraction of
inspired oxygen (FiO2) ratio (PaO2/FiO2 \ 300 mmHg for
ALI and \200 mmHg for ARDS) with normal hydrostatic
pressure corresponding to the absence of left heart failure.
Acute respiratory distress syndrome can occur with several
diseases either associated with those causing direct lung
injury such as pneumonia, gastric aspiration or toxic
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inhalation, or indirect injury such as sepsis or severe burn.
The heterogeneity of causes and the complexity of clinical
histopathological and radiographic manifestations make
the study of ARDS pathogenesis and the test of new
therapeutics difficult. Indeed, ARDS follows most often a
progressive course characterized by two distinct stages.
The acute (or exudative) stage includes the disruption of
the alveolar-capillary barrier, pulmonary edema, accumu-
lation of protein-rich fluid into the interstitium, alveolar
space, and diffuse inflammation. The later organizing stage
occurs with the resolution of pulmonary edema and lung
inflammation. During this phase, alveolar pneumocytes
hyperplasia and fibroblast proliferation lead to disordered
collagen deposition and extensive lung fibrosis.
Although the elucidation of the cellular and molecular
mechanisms involved in the pathogenesis of ALI/ARDS
remain unclear and complex, there is evidence that reactive
oxygen species (ROS) contribute to the initiation of
endothelial damage characteristic of ARDS and are
responsible for most of clinical symptoms of this syndrome
[1]. Indeed, a large amount of ROS, which are found in
broncho alveolar lavages (BAL) of ARDS patients are
produced mainly by alveolar macrophages, neutrophils,
lung endothelial, and epithelial cells. These ROS can alter
gene and protein function. Among several ROS-producing
enzymes, NADPH oxidase (NOX) enzymes, which are
membrane-bound complexes catalyzing the reduction of
molecular oxygen (O2) to superoxide (O2
-) [2], are
involved in principal clinical manifestations of ALI/ARDS
[1, 3]. The first NOX has been described in phagocytes and
is a complex that includes a catalytic subunit gp91phox
called NOX2 associated with p22phox and cytosolic regu-
latory subunits such p47phox, p67phox and small GTPase
(RAC1 or RAC 2), required for NOX activation and gen-
eration of superoxide [2, 4]. Recently, structural
homologues of the phagocyte NOX enzyme were identi-
fied, such as NOX1-3-4-5, DUOX1, and DUOX2. Despite
their similar structure and enzymatic function, NOX
enzymes differ in their mechanisms of activation, which
depend on the recruitment of membrane or/and cytosolic
regulatory subunits such as p22phox, p47phox, p67phox,
NOXO1, NOXA1, and RAC [2]. The NOX isoforms,
which are expressed in a variety of lung cell types [5],
participate in several cellular processes [6] and are
involved in lung pathological situations such as ALI/
ARDS, cancer, fibrosis, pulmonary hypertension, and
obstructive lung disorders such as emphysema, asthma, and
cystic fibrosis [5, 7–10].
In the present article, we will focus on the contribution of
NOX enzymes in the development of ALI/ARDS. We will
first briefly describe some cellular aspects of NOX locali-
zation and function in the lungs. In the second part, we will
review the current knowledge concerning the role of NOX-
dependent ROS production in the pathogenesis of ALI/
ARDS and particularly its involvement in some clinical
aspects of this disease. In the third part, we will discuss their
therapeutic potential in the management of ARDS/ALI.
Cellular expression and function of NOX enzymes
in lungs
The lung, of which the principal function is to deliver
oxygen to tissues, is widely exposed to deleterious envi-
ronmental factors including virus, bacteria, irritants and
allergens, and possesses a potent innate defense system.
This defense system not only uses the phagocyte NOX
system to eliminate these dangers through oxidative killing
[6, 11] but also in regulating cell-signaling pathways
involved in host defense mechanisms, cell proliferation,
migration, and/or differentiation [4, 12]. Several studies
have shown that NOX enzymes are expressed in lungs,
both in mice and in humans. The amount of the different
NOX isoforms depends on the cell types and also on the
species. A high amount of NOX2 [13, 14] and DUOX1/2
mRNA [15, 16] as well as NOX1 [17, 18] and NOX4 [7, 8,
13, 18] are detected in lungs. In addition to the expression
of NOX2 in alveolar macrophages and other inflammatory
cell types, NOX isoforms have been detected in different
lung cell types such as alveolar epithelial and endothelial
cells, fibroblasts, smooth muscle cells, and airway epithe-
lial cells [19, 20]. The cell-type-dependent NOX
expression in lungs suggests their specific participation in
some aspect of physiological and pathological functions
including host defenses, proliferation, migration, and/or
differentiation. The specific lung expression and function
of NOX enzymes are summarized in the Table 1.
Thus, according to the physiological contribution of
NOX enzymes in tissue repair and/or remodeling, we could
envisage that the modulation of their expression and acti-
vation in different lung cell types contributes to the
development of lung diseases such as ALI/ARDS. We will
first describe the pathogenesis of ALI/ARDS and then the
role of ROS-dependent NOX enzymes in different animal
models of ARDS/ALI.
Histopathology and pathogenesis of ALI/ARDS
In spite of the scarce knowledge concerning the mecha-
nisms involved in the pathogenesis of ALI/ARDS,
histological analysis of lung sections from ARDS at dif-
ferent stages suggests that lung modifications occurring
during this disease follow a scheduled time course and can
be divided into three time-dependent phases: acute (or
exudative), proliferative, and fibrosis [61].
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The acute phase begins after the initial injury; most cells
composing the alveolar septa undergo either apoptosis or
necrosis, and inflammatory cells mainly represented by the
neutrophils, invade alveolar walls and lumens. The number
of neutrophils increases fast as they travel via the inter-
stitium into the airspaces. This is facilitated by the
disruption of the vascular structures, which occurs when
neutrophils and fibrin plugs occlude the capillaries
(Fig. 1a, b). Hyaline membranes (HM) made of fibrin,
proteins and cellular debris; accumulate along the alveolar
walls (Fig. 1a, b). By electron microscopy, all stages of
epithelial degeneration can be observed from slight cyto-
plasmic swelling to huge blister formation and total
destruction of the epithelial lining [62]. In parallel, the
endothelial cell layer is often irregular because of cyto-
plasmic swelling and large vacuoles. Endothelial defects
Table 1 Summary of NOX enzymes localization, activation, and function in lung cells
NOX
isoforms
Expression Stimuli Function Species References
NOX1 Endothelial cells FGF-b, VEGF Vascular cell growth M, H [21]
FGF-b, VEGF Angiogenesis M, H [21]
Hyperoxia Cell death M [17]
Alveolar epithelial
cells
TNF-a, hyperoxia Cell death M [17, 22]
Hypoxia HIF-a signaling H [23, 24]
Growth factors, HIPK2 depletion Proliferation M, H [25, 26]




– N.D R [27]
NOX2 Endothelial cells Hyperoxia Cell migration H [28, 29]
Ischemia and High K?, hypoxia Oxygen sensing B, M [30–33]
LPS, TNF-a TLR2 crosstalk M [34]
Neuro-epithelial
cells





TNF-a, LPS influenza A virus Anti-microbial host defense/innate
immune response
M, H [34, 36–41]
Chronic fine particulate TLR4 crosstalk, NF-jB activation M [42]
NOX3 Endothelial cells – TLR4 crosstalk M [10]
Hyperoxia Cell integrity M [43]
NOX4 Endothelial cells Hyperoxia Cell migration H [28, 44]
Alveolar epithelial
cells
Bleomycin, TGF-b1, fine particles Cell death M, H [7, 45]
Smooth muscle
cells




Bleomycin, TGF-b1, radiation Differentiation/activation M, H [7, 8, 48, 49]
Hypoxia Proliferation H [50]
DUOX1 Bronchial cells Pseudomonas aeruginosa, LPO, IL-4, IL-13
cytokines, and cigarette smoke
Host defense H [15, 19, 20,
51–54]
PMA, human neutrophil elastase Mucin expression H [55]
ATP Cellular migration H [56]
– H? production and secretion H [57]
LPS Cell proliferation M [58]
Alveolar epithelial
cells
Hormone mixture Differentiation H [59]
DUOX2 Bronchial cells IFN-c Host defense H [19, 60]
– H? production and secretion H [57]
Alveolar epithelial
cells
– N.D M Personal
data
M mouse, H human, R rat, Ra rabbit, B bovine, PMA phorbol 12-myristate 13-acetate, HIPK2 homeo domain-interacting protein kinase-2, LPO
lactoperoxidase, ATP adenosine triphosphate, ANPH atrial natriuretic peptide hormone, N.D not determined
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are covered by fibrin or microthrombi, which completely
obliterate the capillaries (Fig. 1b, enlarged insert). Con-
cerning the late exudative stage, the epithelial lining is thin
and covered by laminated paucicellular HM. The alveolar
septa are enlarged and contain numerous inflammatory
cells.
After approximately 7 days, the organizing or prolifera-
tive stage is observed with increased interstitial cellularity.
The number of large cuboidal cells, which resemble epi-
thelial type II cells and might represent a stem cell population
of the lung (Fig. 1c and d), increases strikingly. The com-
position of the interstitial cells changes; neutrophils are
partly replaced by macrophages, lymphocytes, and plasma
cells. The interstitium is organized by the proliferation of
connective tissue, persisting edema, and convolutes of loose
fibrous tissue without capillaries. There is a strong diminu-
tion of the microvasculature that is sometimes compressed
by the surrounding tissue. Myofibroblasts that express
vimentin and a-smooth muscle actin (a-SMA) are progres-
sively observed in interstitium and then in airspaces, with a
maximum in the early proliferative stage [63]. The late
proliferative phase shows easily identifiable proliferating
intra-septal and/or intra-alveolar myofibroblasts (airspace
fibroplasia) and production of new matrix substances with
the doubling of lung collagen in 2 weeks.
After a few more days, the fibrotic phase shows wide
connective tissue area interspread between alveolar septa.
Bulk tissue masses formed by folded up septa and col-
lapsed alveoli surround unusually wide airspaces, which
originated mostly from widened alveolar ducts or respira-
tory bronchioles. Some airspace is enlarged due to tissue
destruction. The histology is characterized by enlarged
fibrotic septa and laminated intra-alveolar fibrosis.
ROS are increasingly considered key substances in the
initiation of endothelial damage characteristic of ARDS
and are responsible for most of the clinical symptoms of
this syndrome. There are several causes that increase oxi-
dative stress in ARDS such as breathing high inspiratory
oxygen concentration. However, the large majority of
oxidants are generated by phagocytic cells transmigrating
into the lungs. Neutrophils are crucial since they appear
early in histological specimens and are strongly increased
in the BAL. They release many inflammatory mediators














Fig. 1 Histological hallmarks of acute respiratory distress syndrome
during the exudative and the proliferative phases. a, b Lung sections
stained with hematoxylin and eosin (H&E) obtained from biopsy of
ARDS subjects during the exudative phase. a Deposition of hyaline
membranes (HM) on the epithelial side of the basement membrane.
At this stage, the presence of detached epithelial type II cells from the
alveolar wall (EII) is also apparent. b The presence of the interstitial
edema (E). The necrosis of endothelial cells (En) and the formation of
thrombus associated with the margination of neutrophil (TN) are also
obvious at this stage. Original magnification 9400 (a and b), 9500
for enlarged insert. c, d Lung sections stained with (H&E) obtained
from biopsy of ARDS subjects during the proliferative phase. c, d The
evident hyperplasia of epithelial type II cells (EII) and an extended
zone of interstitial (IN) fibro-proliferation. Note the presence of
myofibroblasts in the parenchyma (MF). Original magnifications
9200 (c), 9400 (d)
2376 S. Carnesecchi et al.
123
The activation of the neutrophils may occur at remote sites
and/or by circulating cytokines, resulting in ROS release
and increased pulmonary vascular permeability. However,
neutrophils are not mandatory for the development of
ARDS, because it can occur in neutropenic patients. Other
key initiators of the pulmonary inflammation in ARDS are
the circulating inflammatory mediators (e.g., TNF-a, IL-
1b, IL-6, IL-8, leukotrienes), as well as changes in the
coagulation system. Alveolar edema resulting from endo-
thelial dysfunction and loss of epithelial integrity reduces
the barrier function. The edema is even increased by the
loss of type II pneumocytes that normally promote fluid
transport out of the alveolus through their apical sodium
pumps. Early loss of surfactant is explained by the damage
of type II epithelial cells, which produce surfactant and by
its neutralization by protein-rich edema fluid. This con-
tributes to alveolar collapse, intrapulmonary shunt, and
hypoxemia. The hypoxic pulmonary vasoconstriction is
impaired by endothelial and smooth muscle cell dysfunc-
tion. This may, with the association of microthrombi,
contribute to the development of secondary pulmonary
hypertension.
Role of NOX enzymes in ALI/ARDS
Whereas the mechanisms that initiate ALI/ARDS remain
unclear, there is some evidence that ROS generated by
NOX enzymes participate in the pathogenesis of this syn-
drome. The study of NOX enzyme contribution in the
patho-mechanisms of ALI/ARDS in human is difficult due
to the heterogeneity of causes and the paucity of biological
samples (biopsies, autopsies, BALF). Animal models
reproduce major clinical features of ALI/ARDS observed
in humans including the loss of the alveolar-capillary
barrier with the damage of both epithelial and endothelial
cells and the inflammatory cell influx. In this way, all these
models provide key elements to study the role of the NOX
family during ALI/ARDS. In the next part, we will
examine their involvement in different mouse models of
ALI/ARDS that mimic neutrophilic infiltration and lung
injury in sepsis-like models and the damage of the alveolar-
capillary barrier.
Lung inflammation and injury
Histological analysis of lung sections from ARDS patients
as well as BAL obtained in the acute phase of the disease
show massive accumulation of neutrophils [64] and most
acute lung injuries induced in animal models are neutro-
phil-dependent [65–67]. These inflammatory cells produce
high levels of ROS, which are thought to increase the
inflammatory processes and tissue injury in septic shock
syndrome [68–70]. In addition, ROS participates in the
modulation of cell-signaling pathways that activate tran-
scription factor of redox-sensitive pro-inflammatory
mediators such as NF-jB [71, 72]. The studies concerning
the effect of ROS generated by NOX enzymes in acute
inflammatory responses and lung injury following Esche-
richia coli and lipopolysaccharide (LPS) challenges in
mice are controversial [37, 71, 73, 74]. Indeed, some
studies have shown that the absence of p47phox (a regula-
tory subunit essential for NOX2 activation) did not
contribute to LPS-induced lung damage, vascular leakage,
and infiltration of neutrophils and monocytes in mice [75].
Swain et al. [76] did not observe any improvement of
pulmonary lung injury in gp91phox-deficient mice during
pneumocystis pneumonia. By contrast, it has been dem-
onstrated that LPS-induced inflammation and lung injury
was inhibited but also in some cases increased in NOX-
deficient mouse models. The absence of p47phox and
gp91phox has been associated with enhanced inflammatory
gene expression, lung neutrophil recruitment, and mouse
survival after LPS challenge [77, 78]. On the other hand,
LPS-induced lung inflammation was reduced in mice
deficient for Nrf2, a regulator of antioxidant defenses, in
absence of p47phox or gp91phox [37]. Moreover, ROS pro-
duction restricted to macrophages from Nrf2-deficient mice
was blunted by the absence of gp91phox after LPS challenge
[37]. Similarly, inflammatory response induced by live
Escherichia coli or LPS was reduced in lung tissues of
p47phox- and gp91phox-deficient mice [71, 73]. Sadikot et al.
[74] has reported that NF-jB activation and TNF-a levels
were decreased in p47phox-deficient mice after Pseudomo-
nas aeruginosa infection and a recent study showed that
ROS generated by NOX2 in neutrophils were involved in
TNF-a-induced acute lung injury [38] and participated in
inflammatory response through the activation of NF-jB
[36]. These results support the notion that ROS generated
by NOX2 play a critical role in the induction of inflam-
matory responses and tissue injury in sepsis.
The family of Toll-like receptors (TLR), which to date
contains ten members, recognizes specific molecules con-
served among microorganisms and pathogens, and plays an
important role in initiating the inflammatory response [79].
Emerging evidence demonstrates that NOX enzymes
modulate Toll-like receptor 4 (TLR4) and TLR2 signaling
not only in neutrophils and macrophages but also in other
cells. Lipopolysaccharide specifically binds to LPS-binding
protein (LBP) and forms a complex that activates the TLR4
receptor of macrophages and others cells. This interaction
triggers the activation of Ijb kinase and the mitogen-acti-
vated protein kinase kinases (MAPKK), which in turn
activate NF-jB and AP1, respectively [80]. Activated
NF-jB and AP-1 translocate into the nucleus where they
bind to DNA promoter regions and induce the transcription
NOX enzymes and acute lung injury 2377
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of inflammatory genes. It has been shown that in neutrophils,
NOX2-derived ROS regulate the TLR4-mediated activa-
tion of NF-jB. In addition, in endothelial cells, NOX2 also
contributes to TLR2 gene activation in response to LPS
[36, 81]. A recent study demonstrated that ROS generated
by NOX2 in neutrophils mediates high mobility group box
1 (HMGB1)/TLR4 signaling and tissue damage after
hemorrhagic shock/resuscitation in mice [82]. Besides
NOX2, NOX4 is able to directly interact with TLR4 and
mediate ROS generation and NF-jB activation in
HEK293T cells [83]. More recently, NOX4 has been
shown to mediate LPS-induced NK-jB-dependent IL8,
MCP-1 and ICAM-1 gene expression in human aortic
endothelial cells [84] and interferon regulatory factor
(IRF)-3 transcription factor activation in U373/CD14 cells
[85]. NADPH oxidase4 is also able to activate AP-1 and
subsequent CXCR6 expression, after LPS challenge in
human aortic smooth muscle cells [86]. Similar to NOX4,
the presence of crosstalk between NOX1 and TLR4 was
suggested by the observation that LPS derived from Heli-
cobacter pylori increases ROS production and NOX1
expression in guinea pig gastric pit cells through a TLR4
signaling pathway [87]. All these results suggest that NOX
family plays an important role in the activation of TLR4
signaling pathways (including NF-jB, IRF-3 and AP1) in
response to LPS. Nevertheless, the molecular mechanism
linking TLR4 to NOX1 remains unclear and the function of
NOX1 and NOX4 in TLR-mediated signaling in vivo need
to be elucidated using either knock-out mice or RNA
interference strategy.
Endothelial and epithelial targets
Alveolar cell death has been reported extensively in
humans and in experimental models of acute lung injury
[88]. Indeed, in the acute phase, the presence of edema in
the air spaces and hyaline membrane deposits are direct
consequences of alveolar-capillary barrier damage. Epi-
thelial type II cells after being initially injured, often by an
unknown stimulus, proliferate in order to repair the dam-
aged epithelium [89]. To date, it is not known whether the
alveolar-capillary barrier integrity depends preferentially
on the endothelial or the epithelial side in acute lung
damage and which are the signaling pathways involved in
alveolar cell death. Nevertheless, there is evidence that
both epithelial and endothelial cells are damaged by ROS-
dependent mechanisms and in particular by NOX-depen-
dent ROS generation.
Endothelial cell target
The injury of endothelial cells is mostly studied in sepsis-
like models using systemic injection of LPS or TNF-a.
During ALI, the endothelium undergoes large transforma-
tions in terms of expression of adhesion molecules, tight
junctions, and ROS-producing enzymes [90]. In this con-
text, NOX-derived ROS participates in the damage of
endothelial cells either by the direct activation of endo-
thelial signaling or via neutrophils or macrophages.
Lipopolysaccharide can directly increase ROS genera-
tion through the modulation of NOX enzymes in
endothelial cells [91]. A recent study demonstrates that in
these cells, stimulation by LPS leads to the activation of
IL8, which in turn regulates the expression and the activity
of NOX1 and contributes to the progression of the sepsis
cascade. These data suggest that LPS/IL8 signaling is
NOX1-dependent in endothelial cells [92]. In addition to
NOX1, NOX4, which is also expressed in endothelial cells,
is responsible for LPS/TLR4-induced ROS generation and
gene expression of chemokines such as IL8, MCP-1, and
intracellular adhesion molecule-1 (ICAM-1) in human
aortic endothelial cells [84]. The authors also demonstrated
that the specific inhibition of NOX4, by siRNA strategy,
contributes to the decrease of LPS-induced migration and
adhesion of monocytes to endothelial cells [84].
Thus, besides the direct effect of LPS on NOX activa-
tion in endothelial cells, excessive production of ROS by
NOX enzymes located in inflammatory cells has been
associated to endothelial cell damage in sepsis. Fan et al.
[34, 81] and others demonstrated that in endothelial cells,
LPS/TLR4-induced NF-jB and TLR2 gene activation is
dependent on NOX2 located in neutrophils. In addition,
neutrophilic NOX2 contributes to TNF-a-induced NF-jB-
dependent lung inflammation and endothelial cell injury in
mice [38] and participates in the activation of NF-jB and
the induction of TLR2 in endothelial cells [36]. More
recently, Farley et al. [41] reported that co-culture of
p47phox and gp91phox-deficient macrophages with pul-
monary microvascular endothelial cells stimulated with a
mix of cytokines such as TNF-a, IL1-b, and IFN-c led to a
significant decrease in endothelial cell injury, supporting
the concept that ROS produced by phagocytic NOX2 play
a crucial role in the injury of endothelial cells.
Epithelial cell target
Although the epithelial barrier after being injured by an
unknown stimulus is mostly able to repair, the persistence
of a lung injury leads to the development of fibrosis. It is
considered that epithelial cell death is crucial not only in
the weakening of the alveolar-capillary barrier, but also in
lung abnormal repair, which leads to pulmonary fibrosis
[93]. While the pathogenesis of pulmonary fibrosis, a lethal
lung disorder characterized by abnormal lung repair, is
unknown, it involves early inflammatory steps and late
fibrotic changes with proliferation of fibroblasts and their
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differentiation into myofibroblasts [94, 95]. Intratracheal
instillation of bleomycin in mice, a well-known charac-
terized model to study initial lung epithelial injury and
subsequent fibrosis, mimics ALI/ARDS features occurring
during the late proliferative and fibrotic phase. In this
model, NOX-dependent ROS are not only responsible for
initial epithelial damage but also for the differentiation of
fibroblasts into myofibroblasts, the hallmark of the disease.
Several studies have shown that TGF-b1 increases ROS
levels by up-regulating NOX4 expression in lung fibro-
blasts and induces their differentiation into myofibroblasts
[8, 96, 97]. Interestingly, in human idiopathic pulmonary
fibrosis (IPF), NOX4 has been detected in myofibroblasts
of late fibrotic scars, suggesting a possible role of NOX4 in
the development of organized fibrosis, and was also
detected in the alveolar proliferative epithelium of IPF
lungs adjacent to fibroblastic foci. In mice, we demon-
strated that NOX4 deficiency as well as acute treatment
with NOX inhibitors blunted TGF-b1-induced alveolar
epithelial cell death and prevented subsequent pulmonary
fibrosis [7].
The role of NOX2 and NOX1 in bleomycin-induced
lung fibrosis has also been investigated in NOX2 and
NOX1-deficient mice. Only a moderate protection from
bleomycin-induced lung fibrosis was observed in NOX2-
deficient mice [98]; however, extrapolation to human IPF is
difficult as inflammation might not be as prominent in
humans compared to mice. We found that NOX1-deficient
mice were not protected from bleomycin-induced fibrosis
(personal data). Finally, NOX4 rather than NOX1 and
NOX2 could be a good candidate for the treatment of
ARDS/ALI patients during both the acute and the prolif-
erative stage.
Epithelium and endothelium targets
Aspiration of the gastric content is considered to be an
important cause of ALI/ARDS. In addition to the low pH,
the gastric content contains particulate bacterial material,
which contributes to lung injury [99]. The intratracheal
instillation of hypochlorite (HCl) is a well-used model for
inducing lung injury secondary to gastric acid aspiration in
mice. Aspiration-induced lung injury, which depends on
neutrophilic influx into the alveolar space, is characterized
by the damage of both epithelial and endothelial cells
leading to alveolar hemorrhage and edema. Some studies
have implicated ROS as a key element in the pathogenesis
of ALI/ARDS following gastric content aspiration in
mouse models [100], but to date, only one has demon-
strated the role of NOX enzyme in this context. Indeed,
exposure of p47phox-deficient mice to HCl leads to
increased pulmonary neutrophilic infiltration, alveolar-
capillary barrier leakage, and enhanced level of pro-
inflammatory cytokine compared to WT mice [101], sug-
gesting a protective role of NOX2 in HCl-induced lung
injury by modulating the inflammatory response.
Mechanical ventilation (MV) is the unique strategy used
in patients with acute hypoxemic respiratory failure to
improve arterial oxygenation and their survival [102].
However, this therapy provokes tissue injury due to
mechanical stretch (MS). Mechanical ventilation associ-
ated with alveolar barrier overstretching contributes to
neutrophilic infiltration, release of pro-inflammatory cyto-
kines, and lung injury [103]. The cellular mechanisms
involved in MV-induced lung injury (MVILI) and
-inflammation remain unknown. A high level of ROS is
thought to be one potential initiating signal in response to
MV following mechanical stress. Indeed, treatment with
N-acetyl cysteine (NAC) attenuates MV-induced neuro-
philic influx into alveolar spaces and reduces epithelial cell
apoptosis in rats [104, 105]. Besides mitochondrial
enzymes, NOXes have been shown to contribute to ROS
production in response to mechanical stress in different
cells such as endothelial cells, epithelial cells, and vascular
smooth muscle cells [106–111]. It has been described that
NOX activation was associated with a membrane translo-
cation of p47phox in smooth muscle cells (SMC) [108, 109].
On the other hand, exposure of vascular SMCs to MV
leads to p47phox membrane translocation followed by an
increased NOX1 mRNA expression and ROS production
[108], suggesting a role for NOX1 in MVILI. Some studies
also demonstrated that ROS produced by NOX enzymes
participated in cyclic stretch-induced vascular remodeling
in SMC via matrix metalloproteinase-2 activation [108].
The NOX isoform involved in MV-induced lung injury and
the NOX-dependent signal transduction pathways need to
be clarified.
Hyperoxia-induced acute lung injury is one of the most
relevant models of oxidative stress and alveolar cell death,
which is not closely linked to the magnitude of the
inflammatory response. In rodents and in alveolar cell
culture, oxygen toxicity (100 % O2) has been used as a
well-established model of lesions mimicking the acute
phase of ALI/ARDS and for studying direct alveolar
damage induced by high levels of oxidants. It was first
explored in rats and later extensively characterized in mice
[112–114]. During the initiation phase (usually lasting for
48 h), only subtle changes can be detected, such as the
arrest of cell replication, and lesions are not evident on
light microscopy. This phase is followed by diffuse alve-
olar damage with hyaline membrane deposition and
extensive death of alveolar cells (mainly endothelial and
epithelial cells) associated with a generally mild inflam-
matory response, which can vary according to the species
[115]. Alveolar cell death has been shown to be directly
related to increased generation of oxidant in hyperoxic
NOX enzymes and acute lung injury 2379
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condition [116]. Reactive oxygen species can be generated
by mitochondrial chain transport as well as by NADPH
oxidase enzymes [117]. In vitro studies have shown that the
diphenyleneiodonium (DPI), a non-specific inhibitor of
NOX isoforms, was effective in reducing hyperoxia-
induced ROS generation in a pulmonary epithelial cell line
(MLE-12) and in primary pulmonary type II cells [117–
119]. Recently, our laboratory demonstrated that NOX1,
which is highly expressed in lungs, plays a crucial role in
hyperoxia-induced acute lung injury [17]. NADPH oxi-
dase1-deficient mice exposed to hyperoxia exhibited
reduced pulmonary edema, hyaline membrane deposition,
and alveolar-capillary damage. Indeed, in situ lung cell
death was markedly decreased in NOX1-deficient mice and
paralleled with decreased ROS production and cell death in
endothelial and epithelial cells. The phosphorylation of
both c-Jun N-terminal kinase (JNK) and extracellular sig-
nal-regulated kinase (ERK), as well as caspase-3 activation
were decreased in lung homogenates. All these results
demonstrate a role for NOX1 in hyperoxia-mediated bar-
rier dysfunction; however, the question of the contribution
of NOX1 restricted to the epithelial side or to endothelial
side or both in ALI/ARDS and its precise cellular signaling
pathway is still open.
As stated above, the integrity of the alveolar-capillary
barrier depends not only on the epithelium but also on the
endothelium. Recent studies have shown increased NOX1
mRNA expression in mouse lung endothelial cells after
hyperoxic condition [17, 28] as well as NOX1 contribution
to endothelial cell death [17]. The involvement of NOX4 in
hyperoxic cultured endothelial cells (EC) has also been
investigated. NADPH oxidase4 mRNA expression is
increased in hyperoxia [28] through direct modulation of
gene transcription. Indeed, direct interaction between nrf2
transcription factor and NOX4 promoter has been reported.
The authors demonstrated that hyperoxia increased the
recruitment- and the binding of nfr2 to endogenous NOX4
promoter via antioxidant response element (ARE) in pul-
monary endothelial cells [44]. Hyperoxia also regulates
NOX activation in part by ERK1/2 and p38 MAPK [117],
but also by an Src-dependent tyrosine phosphorylation of
p47phox [29]. It has also been proposed that NOX2 could be
activated by tyrosine phosphorylation of cortactin and
p47phox translocation following hyperoxia in ECs derived
from human pulmonary artery [120]. Recently, Pendyala
et al. [28] demonstrated the contribution of NOX4 in
endothelial dysfunction. They showed that the transfection
of a NOX4-specific siRNA in HPAEC attenuated hyper-
oxia-induced migration and capillary tube formation.
Therefore, we have now convincing evidence of NOXs
activation (NOX1, 2 and 4) by oxidative stress in murine
and human endothelial cells [17, 29, 117, 120, 121].
Although we have less evidence, we could also hypothesize
that NOX4 participates in epithelial cell damage in ALI/
ARDS. Indeed, we recently reported that NOX4 mRNA
was expressed in primary type II epithelial cells and
mediated TGF-b1-induced epithelial cell death [7]. These
results suggest that NOX4 contributes not only to the
dysfunction or death of endothelial cells, but it might be
involved in the alveolar-capillary disruption observed in
ALI/ARDS. However, all these experiments were per-
formed essentially in cell cultures and should be confirmed
first by using NOX4-deficient mice or/and transfection of
NOX4-specific siRNA and then in humans.
Controversial studies concerning the role of NOX2 in
hyperoxia-induced lung injury have been reported.
Pendyala showed that NOX2-deficient mice exposed to
acute hyperoxia developed attenuated pulmonary edema,
lung fibrosis, and weak inflammatory response [122]. By
contrast, we found that NOX2-deficient mice exposed to
hyperoxia were not protected and display a huge neutrophil
influx in BAL, alveolar cell death, and lung injury [17],
suggesting that NOX2 does not mediate alveolar-capillary
disruption in hyperoxia. Indeed, neutrophil or macrophage
depletion did not change lung damage in hyperoxic lung
injury [123, 124]. Similarly, NOX2-deficient mice exposed
to 48 h of hyperoxia following acid aspiration showed a
greater amount of neutrophils compared to WT mice,
without modification of lung injury [73].
NOX as treatment of ALI/ARDS
As largely described above, NOX inhibitors might have
potential in vivo use in ARDS. However, the multiplicity
of lung cells combined with the cellular and functional
specificity of the different NOX isoforms makes this
approach delicate. Moreover, the measurement of NOX
activity is often indirect since it is evaluated by the dosage
of ROS-derived products using colorimetric or fluorescent
probes. One must be aware that measuring ROS or derived
products levels might not only be due to ROS production
by NOX enzymes but also by other ROS-producing
enzymes. Therefore the specific efficacy of NOX inhibition
can be difficult to prove.
Today, therapeutic intervention for ALI/ARDS consists
of protecting the lung by using adaptive mechanical ven-
tilation and oxygenation and thus limiting mortality [125].
Lung-protective mechanical ventilation with lower tidal
volumes in patients not suffering from acute lung injury: a
review of clinical studies. This strategy was elaborated
according to the results obtained in clinical trials and in
experimental animal models [126]. Some studies have
suggested that subgroups of patients may benefit from
targeted therapeutic interventions. Most promising is the
differentiation between patients in early versus late-phase
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ARDS, direct versus indirect lung injury, and patients with
altered coagulation. A high dose of corticosteroid admin-
istration did not improve mortality, whereas low to
moderate doses appear to be harmful if initiated later and
are of unclear benefit [127, 128]. Surfactant supplementa-
tion was shown to be helpful only in pediatric patients with
direct lung injury [129] and anticoagulants may be suc-
cessful in the subgroup of patients with vascular disease
[130]. There is an interest in developing NOX inhibitors,
since they can act for some of them in the early phase and
for other in the fibro-proliferative phase. Table 2 summa-
rizes the expected effects of the potential NOX inhibitors
for the treatment of ARDS.
NADPH oxidase1 inhibition might be useful in the acute
phase of ALI/ARDS since it interferes with endothelial and
epithelial cell death either by decreasing oxidative stress-
induced genotoxicity or by affecting MAPK signaling
pathways [17]. However, this study was performed only in
mice and evidence in humans is still required. The possi-
bility that NOX1 inhibition can affect TNF activation
might also be interesting in case of ARDS due to sepsis
[22].
NADPH oxidase2 inhibition effects are more complex
and the results are somehow controversial. NADPH oxi-
dase2 is present mainly in phagocytic cells, but also in a
great amount in endothelial cells. Indeed, changing
phagocyte killing might be dangerous in situations of
ARDS due to sepsis or to unknown origin even if ROS-
produced by NOX2 in other cells might prevent concom-
itantly. In this case, a tagged-cell inhibitor would be ideal,
but at the present time rather difficult.
More promising would be the inhibition of NOX4,
which is present in several lung cells epithelial and fibro-
blasts. Several studies have shown a very robust effect in
decreasing epithelial cell death initiated by TGF-b1 and
myofibroblast differentiation [7, 8]. Moreover, NOX4
action is upstream of the pleiomorph effects of TGF-b1,
and therefore could be more efficient in blocking the TGF-
b1 deleterious cascade. We can also hypothesize, as NOX4
is strongly expressed in epithelial cells and its signaling
potentiates cell death induced by TGF-b1, that NOX4-
specific inhibition could prevent the alveolar-capillary
disruption in the ARDS early phase [7]. NADPH oxidase4
is also involved in TLR4 signaling mediated by LPS and
might therefore participate in endothelial dysfunction [84].
This study has been performed in vitro, and more in vivo
data are needed before envisaging therapeutic possibilities.
Conclusions
NADPH oxidase enzymes, which are widely expressed in
different lung cell types, participate not only in the main-
tenance of physiological processes in lungs but also
contribute to the pathogenesis of acute lung diseases such
as ALI and ARDS. The multiplicity of the well-charac-
terized animal models mimicking ARDS/ALI, the use of
NOX-deficient mice and in vivo siRNA transfection strat-
egies allowed to explore NOX-dependent cellular and
molecular mechanisms involved in the development of the
disease and finally envisage new therapeutic approaches.
Developing NOX inhibitors could therefore be a promising
treatment concept for ARDS/ALI. Nevertheless, at the
present time, no direct method for measuring specifically
NOX-dependent ROS generation has been developed to
prove the efficacy of NOX inhibitors and specific inhibitors
for one single NOX isoform are not available. Whether in
some case it might be useful to target two different iso-
forms concomitantly, such as in early phase, in other
situations such as ARDS induced by sepsis, this could be
deleterious due to combined unwarranted secondary
effects. Thus, further in vivo studies concerning NOX
inhibitors are necessary to prove their clinical utility in the
management of ALI/ARDS.
Table 2 Summary of potential effect of NOX inhibitors in ALI/ARDS
NOX isoform
inhibitors
ARDS/ALI clinical stages Target cells Expected effects Secondary effects




Decreased cell death (genotoxicity, MAPK signaling,
TNF-RI-JNK signaling)
N.D




Decreased inflammatory response, endothelial cell




Endothelial cells Decreased cell death, crosstalk with TLR2 signaling N.D
NOX4 Acute stage: alveolar-
capillary barrier disruption





Endothelial cells Decreased cell death,TLR4 crosstalk signaling N.D
Fibro-proliferative stage Myofibroblasts Decreased proliferation and differentiation,
interference with TGF-b1 signaling
N.D
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